This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.
Testing the association between subtypes identified by 5 different clustering approaches and 7 clinical features across 527 patients, 8 significant findings detected with P value < 0.05.
-
CNMF clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'AGE'.
-
CNMF clustering analysis on array-based miR expression data identified 4 subtypes that correlate to 'Time to Death'.
-
Consensus hierarchical clustering analysis on array-based miR expression data identified 3 subtypes that correlate to 'Time to Death' and 'AGE'.
-
3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'Time to Death' and 'AGE'.
Clinical Features |
Statistical Tests |
mRNA CNMF subtypes |
mRNA cHierClus subtypes |
miR CNMF subtypes |
miR cHierClus subtypes |
METHLYATION CNMF |
Time to Death | logrank test | 0.157 | 0.056 | 0.000614 | 0.00455 | 0.00142 |
AGE | ANOVA | 0.0257 | 0.0276 | 0.101 | 0.000872 | 5.2e-08 |
GENDER | Fisher's exact test | 0.497 | 0.563 | 0.555 | 0.14 | 0.849 |
KARNOFSKY PERFORMANCE SCORE | ANOVA | 0.839 | 0.487 | 0.943 | 0.785 | 0.223 |
HISTOLOGICAL TYPE | Fisher's exact test | 0.0487 | 0.592 | 0.234 | 0.324 | 0.793 |
RADIATIONS RADIATION REGIMENINDICATION | Fisher's exact test | 0.263 | 0.138 | 0.423 | 0.821 | 0.144 |
NEOADJUVANT THERAPY | Fisher's exact test | 0.532 | 0.53 | 0.612 | 0.874 | 0.133 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 177 | 172 | 170 |
P value = 0.157 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 519 | 403 | 0.1 - 127.6 (9.9) |
subtype1 | 177 | 145 | 0.2 - 127.6 (10.0) |
subtype2 | 172 | 129 | 0.2 - 108.8 (9.2) |
subtype3 | 170 | 129 | 0.1 - 92.6 (10.7) |
P value = 0.0257 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 519 | 57.7 (14.5) |
subtype1 | 177 | 57.3 (12.8) |
subtype2 | 172 | 55.8 (16.4) |
subtype3 | 170 | 60.0 (13.7) |
P value = 0.497 (Fisher's exact test)
nPatients | FEMALE | MALE |
---|---|---|
ALL | 204 | 315 |
subtype1 | 70 | 107 |
subtype2 | 62 | 110 |
subtype3 | 72 | 98 |
P value = 0.839 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 389 | 77.1 (14.4) |
subtype1 | 137 | 77.5 (15.0) |
subtype2 | 126 | 77.3 (13.0) |
subtype3 | 126 | 76.5 (15.0) |
P value = 0.0487 (Fisher's exact test)
nPatients | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|
ALL | 499 | 20 |
subtype1 | 165 | 12 |
subtype2 | 169 | 3 |
subtype3 | 165 | 5 |
P value = 0.263 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 359 | 160 |
subtype1 | 125 | 52 |
subtype2 | 111 | 61 |
subtype3 | 123 | 47 |
P value = 0.532 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 330 | 189 |
subtype1 | 118 | 59 |
subtype2 | 105 | 67 |
subtype3 | 107 | 63 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 223 | 127 | 169 |
P value = 0.056 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 519 | 403 | 0.1 - 127.6 (9.9) |
subtype1 | 223 | 182 | 0.1 - 90.6 (10.4) |
subtype2 | 127 | 94 | 0.1 - 92.6 (9.8) |
subtype3 | 169 | 127 | 0.2 - 127.6 (9.4) |
P value = 0.0276 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 519 | 57.7 (14.5) |
subtype1 | 223 | 57.7 (13.4) |
subtype2 | 127 | 60.3 (13.8) |
subtype3 | 169 | 55.7 (16.0) |
P value = 0.563 (Fisher's exact test)
nPatients | FEMALE | MALE |
---|---|---|
ALL | 204 | 315 |
subtype1 | 90 | 133 |
subtype2 | 53 | 74 |
subtype3 | 61 | 108 |
P value = 0.487 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 389 | 77.1 (14.4) |
subtype1 | 165 | 77.6 (14.4) |
subtype2 | 98 | 75.6 (15.4) |
subtype3 | 126 | 77.6 (13.5) |
P value = 0.592 (Fisher's exact test)
nPatients | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|
ALL | 499 | 20 |
subtype1 | 212 | 11 |
subtype2 | 123 | 4 |
subtype3 | 164 | 5 |
P value = 0.138 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 359 | 160 |
subtype1 | 161 | 62 |
subtype2 | 91 | 36 |
subtype3 | 107 | 62 |
P value = 0.53 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 330 | 189 |
subtype1 | 147 | 76 |
subtype2 | 81 | 46 |
subtype3 | 102 | 67 |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 144 | 159 | 74 | 105 |
P value = 0.000614 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 482 | 379 | 0.1 - 127.6 (10.3) |
subtype1 | 144 | 116 | 0.1 - 51.3 (10.6) |
subtype2 | 159 | 124 | 0.1 - 127.6 (10.6) |
subtype3 | 74 | 57 | 0.1 - 53.8 (8.4) |
subtype4 | 105 | 82 | 0.1 - 92.6 (10.8) |
P value = 0.101 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 482 | 57.5 (14.6) |
subtype1 | 144 | 59.7 (11.4) |
subtype2 | 159 | 55.5 (17.0) |
subtype3 | 74 | 57.9 (15.3) |
subtype4 | 105 | 57.4 (13.7) |
P value = 0.555 (Fisher's exact test)
nPatients | FEMALE | MALE |
---|---|---|
ALL | 187 | 295 |
subtype1 | 56 | 88 |
subtype2 | 68 | 91 |
subtype3 | 27 | 47 |
subtype4 | 36 | 69 |
P value = 0.943 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 368 | 77.6 (14.1) |
subtype1 | 112 | 77.6 (14.4) |
subtype2 | 114 | 77.5 (14.1) |
subtype3 | 62 | 76.9 (14.4) |
subtype4 | 80 | 78.4 (13.8) |
P value = 0.234 (Fisher's exact test)
nPatients | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|
ALL | 462 | 20 |
subtype1 | 141 | 3 |
subtype2 | 150 | 9 |
subtype3 | 69 | 5 |
subtype4 | 102 | 3 |
P value = 0.423 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 337 | 145 |
subtype1 | 105 | 39 |
subtype2 | 113 | 46 |
subtype3 | 46 | 28 |
subtype4 | 73 | 32 |
P value = 0.612 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 307 | 175 |
subtype1 | 92 | 52 |
subtype2 | 96 | 63 |
subtype3 | 47 | 27 |
subtype4 | 72 | 33 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 170 | 180 | 132 |
P value = 0.00455 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 482 | 379 | 0.1 - 127.6 (10.3) |
subtype1 | 170 | 137 | 0.1 - 92.6 (9.8) |
subtype2 | 180 | 145 | 0.1 - 127.6 (10.0) |
subtype3 | 132 | 97 | 0.1 - 108.8 (10.7) |
P value = 0.000872 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 482 | 57.5 (14.6) |
subtype1 | 170 | 59.2 (12.6) |
subtype2 | 180 | 58.9 (13.3) |
subtype3 | 132 | 53.5 (17.6) |
P value = 0.14 (Fisher's exact test)
nPatients | FEMALE | MALE |
---|---|---|
ALL | 187 | 295 |
subtype1 | 59 | 111 |
subtype2 | 80 | 100 |
subtype3 | 48 | 84 |
P value = 0.785 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 368 | 77.6 (14.1) |
subtype1 | 129 | 78.3 (13.5) |
subtype2 | 136 | 77.1 (15.5) |
subtype3 | 103 | 77.4 (13.1) |
P value = 0.324 (Fisher's exact test)
nPatients | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|
ALL | 462 | 20 |
subtype1 | 166 | 4 |
subtype2 | 171 | 9 |
subtype3 | 125 | 7 |
P value = 0.821 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 337 | 145 |
subtype1 | 117 | 53 |
subtype2 | 125 | 55 |
subtype3 | 95 | 37 |
P value = 0.874 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 307 | 175 |
subtype1 | 110 | 60 |
subtype2 | 112 | 68 |
subtype3 | 85 | 47 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 79 | 123 | 78 |
P value = 0.00142 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 280 | 208 | 0.1 - 127.6 (10.0) |
subtype1 | 79 | 57 | 0.1 - 92.6 (10.0) |
subtype2 | 123 | 95 | 0.1 - 77.6 (9.4) |
subtype3 | 78 | 56 | 0.2 - 127.6 (11.7) |
P value = 5.2e-08 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 280 | 57.5 (14.9) |
subtype1 | 79 | 57.0 (11.9) |
subtype2 | 123 | 62.4 (12.6) |
subtype3 | 78 | 50.3 (17.7) |
P value = 0.849 (Fisher's exact test)
nPatients | FEMALE | MALE |
---|---|---|
ALL | 114 | 166 |
subtype1 | 34 | 45 |
subtype2 | 50 | 73 |
subtype3 | 30 | 48 |
P value = 0.223 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 213 | 75.4 (15.0) |
subtype1 | 61 | 77.0 (17.1) |
subtype2 | 93 | 73.3 (14.8) |
subtype3 | 59 | 76.8 (12.5) |
P value = 0.793 (Fisher's exact test)
nPatients | TREATED PRIMARY GBM | UNTREATED PRIMARY (DE NOVO) GBM |
---|---|---|
ALL | 261 | 19 |
subtype1 | 73 | 6 |
subtype2 | 116 | 7 |
subtype3 | 72 | 6 |
P value = 0.144 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 209 | 71 |
subtype1 | 64 | 15 |
subtype2 | 85 | 38 |
subtype3 | 60 | 18 |
P value = 0.133 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 201 | 79 |
subtype1 | 62 | 17 |
subtype2 | 81 | 42 |
subtype3 | 58 | 20 |
-
Cluster data file = GBM.mergedcluster.txt
-
Clinical data file = GBM.clin.merged.picked.txt
-
Number of patients = 527
-
Number of clustering approaches = 5
-
Number of selected clinical features = 7
-
Exclude small clusters that include fewer than K patients, K = 3
consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)
Resampling-based clustering method (Monti et al. 2003)
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R
For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
This is an experimental feature. Location of data archives could not be determined.